Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia (Q47877771)

6 February 2018

title

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia (English)

1 reference

6 February 2018

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

7

1 reference

6 February 2018

Timothy Hughes

6

object named as

T P Hughes

1 reference

6 February 2018

author name string

L Schafranek

1

1 reference

6 February 2018

E Nievergall

2

1 reference

6 February 2018

J A Powell

3

1 reference

6 February 2018

D K Hiwase

4

1 reference

6 February 2018

T Leclercq

5

1 reference

6 February 2018

publication date

12 May 2014

1 reference

6 February 2018

published in

Leukemia

1 reference

6 February 2018

volume

29

1 reference

6 February 2018

issue

1

1 reference

6 February 2018

page(s)

76-85

1 reference

6 February 2018

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Gfi-1 inhibits proliferation and colony formation of p210BCR/ABL-expressing cells via transcriptional repression of STAT 5 and Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Low GFI1 expression in white blood cells of CP-CML patients at diagnosis is strongly associated with subsequent blastic transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL(+) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Metabolism and disposition of dasatinib after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.156

The molecular biology of chronic myeloid leukemia.

21 January 2018

1 reference

12 December 2020

Inhibition of human breast cancer cell proliferation in tissue culture by the neuroleptic agents pimozide and thioridazine

1 reference

12 December 2020

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

1 reference

12 December 2020

Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.156

1 reference

6 February 2018

1 reference

6 February 2018